These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 15232725)

  • 21. New options and controversies in the management of chemotherapy-induced nausea and vomiting.
    Koth SM; Kolesar J
    Am J Health Syst Pharm; 2017 Jun; 74(11):812-819. PubMed ID: 28396308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis.
    Zhang Y; Yang Y; Zhang Z; Fang W; Kang S; Luo Y; Sheng J; Zhan J; Hong S; Huang Y; Zhou N; Zhao H; Zhang L
    J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27795228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The current status of the use of palonosetron.
    Navari R
    Expert Opin Pharmacother; 2013 Jul; 14(10):1281-4. PubMed ID: 23647207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).
    Rojas C; Slusher BS
    Cancer Treat Rev; 2015 Dec; 41(10):904-13. PubMed ID: 26442475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
    Navari RM
    Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1577-86. PubMed ID: 19929251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiemetics for cancer chemotherapy-induced nausea and vomiting. A review of agents in development.
    Rizk AN; Hesketh PJ
    Drugs R D; 1999 Oct; 2(4):229-35. PubMed ID: 10659396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
    Perez EA
    Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.
    Bosnjak SM; Dimitrijevic J; Djordjevic F
    Curr Opin Support Palliat Care; 2016 Jun; 10(2):180-8. PubMed ID: 27028050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
    Kim KI; Lee DE; Cho I; Yoon JH; Yoon SS; Lee HS; Oh JM
    Ann Pharmacother; 2012 Dec; 46(12):1637-44. PubMed ID: 23170032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment.
    Aapro M
    Oncology; 2005; 69(2):97-109. PubMed ID: 16131816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?
    de Wit R; Aapro M; Blower PR
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):231-8. PubMed ID: 15838653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review of palonosetron: emerging data distinguishing it as a novel 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting.
    Saito M; Tsukuda M
    Expert Opin Pharmacother; 2010 Apr; 11(6):1003-14. PubMed ID: 20307224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents.
    Navari RM
    Drugs; 2013 Mar; 73(3):249-62. PubMed ID: 23404093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
    Herrstedt J
    Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009.
    Jordan K; Roila F; Molassiotis A; Maranzano E; Clark-Snow RA; Feyer P;
    Support Care Cancer; 2011 Mar; 19 Suppl 1():S37-42. PubMed ID: 20824481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study.
    Matsuda M; Yamamoto T; Ishikawa E; Akutsu H; Takano S; Matsumura A
    Neurol Med Chir (Tokyo); 2016 Nov; 56(11):698-703. PubMed ID: 27666343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Rev Anticancer Ther; 2015; 15(10):1127-33. PubMed ID: 26366937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal selection of antiemetics in children receiving cancer chemotherapy.
    Roila F; Aapro M; Stewart A
    Support Care Cancer; 1998 May; 6(3):215-20. PubMed ID: 9629872
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
    Hesketh PJ; Van Belle S; Aapro M; Tattersall FD; Naylor RJ; Hargreaves R; Carides AD; Evans JK; Horgan KJ
    Eur J Cancer; 2003 May; 39(8):1074-80. PubMed ID: 12736106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.